Elizabeth A Griffiths

Summary

Affiliation: Roswell Park Cancer Institute
Country: USA

Publications

  1. doi request reprint A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia
    Elizabeth A Griffiths
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Sts, Buffalo, NY 14263, United States Electronic address
    Leuk Res 43:44-8. 2016
  2. pmc Epigenetic therapies in MDS and AML
    Elizabeth A Griffiths
    Roswell Park Cancer Institute, Buffalo, NY, USA
    Adv Exp Med Biol 754:253-83. 2013
  3. pmc Myelodysplastic syndromes and autoimmune diseases--case series and review of literature
    Omar Al Ustwani
    Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, USA
    Leuk Res 37:894-9. 2013
  4. doi request reprint Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old
    Neha Gupta
    Department of Medicine, SUNY UB School of Medicine, Buffalo, New York
    Am J Hematol 90:639-46. 2015
  5. doi request reprint Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia
    Monica R Muppidi
    Leukemia Service, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY Electronic address
    Clin Lymphoma Myeloma Leuk 15:S73-9. 2015
  6. pmc Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age
    Carlos E Vigil
    Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, United States
    Leuk Res 37:1468-71. 2013
  7. doi request reprint Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy
    Lin Mei
    Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Blood Rev 29:243-9. 2015
  8. doi request reprint Omacetaxine mepesuccinate in chronic myeloid leukemia
    Omar Al Ustwani
    Roswell Park Cancer Institute, Department of Medicine, Leukemia Section, Elm and Carlton Street, Buffalo, NY 14263, USA 001 716 845 8447 001 716 845 2343
    Expert Opin Pharmacother 15:2397-405. 2014
  9. doi request reprint Polo-like kinase inhibitors in hematologic malignancies
    Chetasi Talati
    Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA Electronic address
    Crit Rev Oncol Hematol 98:200-10. 2016
  10. doi request reprint Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies
    Britny Rogala
    Roswell Park Cancer Institute, Department of Pharmacy, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Expert Opin Biol Ther 15:895-908. 2015

Collaborators

Detail Information

Publications13

  1. doi request reprint A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia
    Elizabeth A Griffiths
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Sts, Buffalo, NY 14263, United States Electronic address
    Leuk Res 43:44-8. 2016
    ..At the dose and schedule tested, this combination did not appear to result in improved CR over single agent AraC for r/r AML. ..
  2. pmc Epigenetic therapies in MDS and AML
    Elizabeth A Griffiths
    Roswell Park Cancer Institute, Buffalo, NY, USA
    Adv Exp Med Biol 754:253-83. 2013
    ....
  3. pmc Myelodysplastic syndromes and autoimmune diseases--case series and review of literature
    Omar Al Ustwani
    Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, USA
    Leuk Res 37:894-9. 2013
    ..The mechanism(s) of the association between AD and MDS are discussed. Treatment could be targeted against AD, MDS or both, though based on recent reports, treating MDS with hypomethylating agents alone could improve the associated AD. ..
  4. doi request reprint Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old
    Neha Gupta
    Department of Medicine, SUNY UB School of Medicine, Buffalo, New York
    Am J Hematol 90:639-46. 2015
    ..should drive treatment decisions. Prospective randomized trials to determine the optimal induction approach for specific patient subsets are needed...
  5. doi request reprint Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia
    Monica R Muppidi
    Leukemia Service, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY Electronic address
    Clin Lymphoma Myeloma Leuk 15:S73-9. 2015
    ..FLT-3 inhibitors such as sorafenib have been studied as a single agent and in combination with conventional chemotherapy or azacytidine with fair responses...
  6. pmc Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age
    Carlos E Vigil
    Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, United States
    Leuk Res 37:1468-71. 2013
    ..Six (28.6%) patients achieved complete remission including three (21.4%) of 14 patients with unfavorable AML. The median disease-free survival was 6.8 months and the median overall survival was 11.2 months. ..
  7. doi request reprint Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy
    Lin Mei
    Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Blood Rev 29:243-9. 2015
    ..Incorporating recent pharmacogenetic data, mainly from pediatric ALL, will provide novel perspective of predicting response and toxicity in both pediatric and adult ALL therapies. ..
  8. doi request reprint Omacetaxine mepesuccinate in chronic myeloid leukemia
    Omar Al Ustwani
    Roswell Park Cancer Institute, Department of Medicine, Leukemia Section, Elm and Carlton Street, Buffalo, NY 14263, USA 001 716 845 8447 001 716 845 2343
    Expert Opin Pharmacother 15:2397-405. 2014
    ..Omacetaxine mepesuccinate is a semisynthetic derivative of HHT with known clinical activity in relapsed or refractory CML following TKI therapy...
  9. doi request reprint Polo-like kinase inhibitors in hematologic malignancies
    Chetasi Talati
    Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA Electronic address
    Crit Rev Oncol Hematol 98:200-10. 2016
    ..Novel approaches, such as Plk inhibitors, are urgently needed for these patients. Here, we provide a comprehensive overview of the current state of development of Plk inhibitors for the treatment of hematologic malignancies. ..
  10. doi request reprint Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies
    Britny Rogala
    Roswell Park Cancer Institute, Department of Pharmacy, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Expert Opin Biol Ther 15:895-908. 2015
    ..Success comes at the cost of immunological toxicities rarely encountered with previous therapies and challenging administration logistics requiring clinical expertise...
  11. pmc How we will treat chronic myeloid leukemia in 2016
    Chetasi Talati
    Internal Medicine, University at Buffalo, Buffalo, NY, USA
    Blood Rev 29:137-42. 2015
    ..We hope that our message will open communication between providers, insurance companies and healthcare authorities to offer the best care for our patients...
  12. pmc Low 25(OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia
    Hun Ju Lee
    Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York
    Cancer 120:521-9. 2014
    ..Several studies have suggested that low 25(OH) vitamin D3 levels may be prognostic in some malignancies, but no studies have evaluated their impact on treatment outcome in patients with acute myeloid leukemia (AML)...
  13. pmc Interpretation of cytogenetic and molecular results in patients treated for CML
    Carlos E Vigil
    Roswell Park Cancer Institute, Buffalo, NY 14263, United States
    Blood Rev 25:139-46. 2011
    ..The relationship between a complete cytogenetic response at 12 months and long-term PFS supports a role for second-generation TKIs as first-line treatment of newly diagnosed chronic-phase CML...